Generic Name and Formulations:
Dorzolamide HCl 2%; oph soln; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for TRUSOPT:
Open-angle glaucoma. Ocular hypertension.
Adults and Children:
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if ocular effects (eg, conjunctivitis, lid reactions) occur. Soft contact lenses. Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant oral carbonic anhydrase inhibitors: not recommended. May inhibit renal excretion of basic drugs and promote excretion of acidic drugs. May increase salicylate toxicity (acidosis).
Carbonic anhydrase inhibitor (sulfonamide).
Burning, stinging, bitter taste, punctate keratitis, ocular allergic reaction, blurred vision, tearing, dryness, photophobia; possible sulfa-like systemic effects.
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Demoralization Common in Patients With Parkinson Disease
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Migraine a Common Comorbidity in Individuals With Sarcoidosis
- Cardiovascular Risk Factors and Development of Brain Atrophy in Multiple Sclerosis
- Association Between Multiple Sclerosis Relapses and Vaccinations
- Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments